DUS2

Across TCGA pan-cancer cohorts, DUS2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DUS2 data layer compared with 19 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DUS2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated DUS2 expression acts as an unfavorable survival marker.

PDAC, CCRCC, and OV are the cancer types where DUS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.312	0.659	<.001	58	view →
CCRCC	DFS	Tertile	III,IV	0.404	0.790	.014	15	view →
OV	DFS	Median	All	0.656	0.923	.033	8	view →
LSCC	DFS	Tertile	All	0.848	1.000	.031	3	view →
LUAD	OS	Median	III,IV	0.265	1.000	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DUS2–PDAC (OS)

Open the PDAC breakdown →